CWM
NMRA icon

CIBC World Markets’s Neumora Therapeutics NMRA Stock Holding History

CIBC World Markets’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,911
Closed -$18.9K – 1800
2025
Q1 		$18.9K Buy
+18,911
New +$32.4K ﹤0.01% 1798

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CIBC World Markets's NMRA Position: Q2 2025 in Review

CIBC World Markets sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 18,911 shares — an estimated $18.9K sold.

CIBC World Markets first reported a position in NMRA in Q1 2025 and held it in 1 quarter. The position peaked at $18.9K in Q1 2025. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • CIBC World Markets reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 18,911 Neumora Therapeutics shares in Q2 2025, an estimated $18.9K.
  • CIBC World Markets first reported a position in Neumora Therapeutics in Q1 2025 and held it in 1 quarter.
  • CIBC World Markets's Neumora Therapeutics position peaked at $18.9K in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.